Do cancer survivors change their prescription drug use for financial reasons? Findings from a nationally representative sample in the United States

Cancer

Volumn 123, Issue 8, 2017, Pages 1453-1463

  Zheng, Zhiyuan ^a,b   Han, Xuesong ^a   Guy, Gery P ^c   Davidoff, Amy J ^d   Li, Chunyu ^c   Banegas, Matthew P ^e   Ekwueme, Donatus U ^c   Yabroff, K Robin ^f   Jemal, Ahmedin ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d YALE UNIVERSITY   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer survivors; comorbid conditions; financial burden; high deductible plan; prescription drugs

Indexed keywords

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CANCER SURVIVOR; COMORBIDITY; CONTROLLED STUDY; DRUG USE; ETHNICITY; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MEDICAL HISTORY; MIDDLE AGED; PRESCRIPTION; UNITED STATES; YOUNG ADULT; ADOLESCENT; ALTERNATIVE MEDICINE; CROSS-SECTIONAL STUDY; DRUG SUBSTITUTION; ECONOMICS; NEOPLASMS; QUESTIONNAIRE; SURVIVOR;

ANTINEOPLASTIC AGENT; PRESCRIPTION DRUG;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMORBIDITY; COMPLEMENTARY THERAPIES; CROSS-SECTIONAL STUDIES; DRUG SUBSTITUTION; HUMANS; INSURANCE, HEALTH; MIDDLE AGED; NEOPLASMS; PRESCRIPTION DRUGS; SURVEYS AND QUESTIONNAIRES; SURVIVORS; UNITED STATES; YOUNG ADULT;

EID: 85013413472     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30560     Document Type: Article

References (61)

1. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25:1319–1331.
2. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: justum pretium—the just price. J Clin Oncol. 2013;31:3600–3604.
3. Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N Engl J Med. 2014;370:1478–1481.
4. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119:1257–1265.
5. The Henry J. Kaiser Family Foundation. Distribution of Covered Workers Facing Different Cost-Sharing Formulas for Prescription Drug Benefits, 2000-2012. Available at: http://kff.org/health-costs/slide/distribution-of-covered-workers-facing-different-cost-sharing-formulas-for-prescription-drug-benefits-2000-2012/. Accessed September 2015.
6. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29:2821–2826.
7. Guy GP Jr, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol. 2013;20:3749–3757.
8. Ekwueme DU, Yabroff KR, Guy GP Jr, et al. Medical costs and productivity losses of cancer survivors—United States, 2008-2011. MMWR Morb Mortal Wkly Rep. 2014;63:505–510.
9. Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D. Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11:145–150.
10. Ubel PA, Abernethy AP, Zafar SY. Full disclosure—out-of-pocket costs as side effects. N Engl J Med. 2013;369:1484–1486.
11. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–390.
12. Guy GP Jr, Yabroff KR, Ekwueme DU, et al. Healthcare expenditure burden among nonelderly cancer survivors, 2008–2012. Am J Prev Med. 2015;49(6 suppl 5):S489–S497.
13. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–496.
14. Streeter SB, Schwartzberg L, Husain N, Johnsrud M. Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract. 2011;7(3 suppl):46s–51s.
15. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.
16. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–661.
17. Zanders MJ, Haak H, van Herk-Sukel MP, van de Poll-Franse L, Johnson J. Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia. 2015;58:951–960.
18. Stuart BC, Davidoff AJ, Erten MZ. Changes in medication management after a diagnosis of cancer among Medicare beneficiaries with diabetes. J Oncol Pract. 2015;11:429–434.
19. Stavrou EP, Buckley N, Olivier J, Pearson SA. Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage [serial online]. BMJ Open. 2012;2:e000880.
20. Zullig LL, Peppercorn JM, Schrag D, et al. Financial distress, use of cost-coping strategies, and adherence to prescription medication among patients with cancer. J Oncol Pract. 2013;9(6 suppl):60s–63s.
21. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early stage breast cancer. J Clin Oncol. 2011;29:2534–2542.
22. Lee M, Khan MM. Gender differences in cost-related medication non-adherence among cancer survivors. J Cancer Surviv. 2015;10:384–393.
23. Smith JC, Medalia C. US Census Bureau, Current Population Reports, P60–250, Health Insurance Coverage in the United States: 2013. Washington, DC: US Government Printing Office; 2014.
24. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29:235–241.
25. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995;13:235–252.
26. National Center for Health Statistics. Survey Description, National Health Interview Survey, 2013. Hyattsville, MD: Division of Health Interview Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, US Department of Health and Human Services; 2014.
27. Dowling EC, Chawla N, Forsythe LP, et al. Lost productivity and burden of illness in cancer survivors with and without other chronic conditions. Cancer. 2013;119:3393–3401.
28. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96:1322–1330.
29. Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119:3710–3717.
30. Parsons VL, Moriarity C, Jonas K, Moore TF, Davis KE, Tompkins L. Design and estimation for the National Health Interview Survey, 2006-2015. Vital Health Stat 2. 2014;165:1–53.
31. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55:652–659.
32. Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32:1143–1152.
33. Chirikos TN, Russell-Jacobs A, Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract. 2002;10:248–255.
34. de Boer AM, Taskila T, Ojajarvi A, van Dijk FH, Verbeek JM. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009;301:753–762.
35. Sabatino SA, Coates RJ, Uhler RJ, Alley LG, Pollack LA. Health insurance coverage and cost barriers to needed medical care among U.S. adult cancer survivors age <65 years. Cancer. 2006;106:2466–2475.
36. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol. 2012;30:1608–1614.
37. Anvik T, Holtedahl KA, Mikalsen H. “When patients have cancer, they stop seeing me”—the role of the general practitioner in early follow-up of patients with cancer—a qualitative study [serial online]. BMC Family Pract. 2006;7:19.
38. Bayliss EA, Bronsert MR, Reifler LM, et al. Statin prescribing patterns in a cohort of cancer patients with poor prognosis. J Palliat Med. 2013;16:412–418.
39. McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109:1172–1180.
40. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26:61–69.
41. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–311.
42. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439–4442.
43. Virgo KS, Bromberek JL, Glaser A, Horgan D, Maher J, Brawley OW. Health care policy and cancer survivorship. Cancer. 2013;119:2187–2199.
44. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30:91–99.
45. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–530.
46. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27:3868–3874.
47. Irwin B, Kimmick G, Altomare I, et al. Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist. 2014;19:1135–1140.
48. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10:162–167.
49. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–237.
50. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245–3253.
51. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–2577.
52. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–115.
53. Peeters L, Sibille A, Anrys B, et al. Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients' perceptions. J Thorac Oncol. 2012;7:1291–1295.
54. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1:539–540.
55. Brooks GA, Li L, Sharma DB, et al. Regional variation in spending and survival for older adults with advanced cancer. J Natl Cancer Inst. 2013;105:634–642.
56. Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI. Household net worth, racial disparities, and hormonal therapy adherence among women with early stage breast cancer. J Clin Oncol. 2015;33:1053–1059.
57. Klabunde CN, Ambs A, Keating NL, et al. The role of primary care physicians in cancer care. J Gen Intern Med. 2009;24:1029–1036.
58. Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073–1079.
59. Bush TL, Miller SR, Golden AL, Hale WE. Self-report and medical record report agreement of selected medical conditions in the elderly. Am J Public Health. 1989;79:1554–1556.
60. Harlow S, Linet M. Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol. 1989;129:233–248.
61. Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer. 2011;117:2791–2800.